Search

Your search keyword '"Muller RN"' showing total 97 results

Search Constraints

Start Over You searched for: Author "Muller RN" Remove constraint Author: "Muller RN" Topic contrast media Remove constraint Topic: contrast media
97 results on '"Muller RN"'

Search Results

1. Functionalized silica nanoplatform as a bimodal contrast agent for MRI and optical imaging.

2. Mn 2+ Complexes with Pyclen-Based Derivatives as Contrast Agents for Magnetic Resonance Imaging: Synthesis and Relaxometry Characterization.

3. Synthesis and Relaxometric Characterization of New Poly[N,N-bis(3-aminopropyl)glycine] (PAPGly) Dendrons Gd-Based Contrast Agents and Their in Vivo Study by Using the Dynamic Contrast-Enhanced MRI Technique at Low Field (1 T).

4. Fluorinated MRI contrast agents and their versatile applications in the biomedical field.

5. VSION as high field MRI T 1 contrast agent: evidence of their potential as positive contrast agent for magnetic resonance angiography.

6. Optimizing Water Exchange Rates and Rotational Mobility for High-Relaxivity of a Novel Gd-DO3A Derivative Complex Conjugated to Inulin as Macromolecular Contrast Agents for MRI.

7. Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1.

8. Synthesis and characterization of monophosphinic acid DOTA derivative: A smart tool with functionalities for multimodal imaging.

9. (1) H-NMR relaxometric studies of interaction between apoptosis specific MRI paramagnetic contrast agents and micellar models of apoptotic cells.

10. Early detection of colonic dysplasia by magnetic resonance molecular imaging with a contrast agent raised against the colon cancer marker MUC5AC.

11. Entrapment of a neutral Tm(III)-based complex with two inner-sphere coordinated water molecules into PEG-stabilized vesicles: towards an alternative strategy to develop high-performance LipoCEST contrast agents for MR imaging.

12. Bifunctional Gd(III) and Tb(III) chelates based on a pyridine-bis(iminodiacetate) platform, suitable optical probes and contrast agents for magnetic resonance imaging.

13. Mn(II)-containing coordination nanoparticles as highly efficient T(1) contrast agents for magnetic resonance imaging.

14. New carboxysilane-coated iron oxide nanoparticles for nonspecific cell labelling.

15. Fluorometry, a fast screening technique for non-covalent binding of contrast agents to human serum albumin?

16. High-relaxivity and luminescent silica nanoparticles as multimodal agents for molecular imaging.

17. A new metallostar complex based on an aluminum(III) 8-hydroxyquinoline core as a potential bimodal contrast agent.

18. Uniform mesoporous silica coated iron oxide nanoparticles as a highly efficient, nontoxic MRI T(2) contrast agent with tunable proton relaxivities.

19. A tripodal ruthenium-gadolinium metallostar as a potential α(v)β(3) integrin specific bimodal imaging contrast agent.

20. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives.

21. Effect of nonenzymatic glycosylation on the magnetic resonance imaging (MRI) contrast agent binding to human serum albumin.

22. Polyglycerol-grafted superparamagnetic iron oxide nanoparticles: highly efficient MRI contrast agent for liver and kidney imaging and potential scaffold for cellular and molecular imaging.

23. A self-assembled complex with a titanium(IV) catecholate core as a potential bimodal contrast agent.

24. The Gd3+ complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(p-isothiocyanatoanilide) conjugated to inulin: a potential stable macromolecular contrast agent for MRI.

25. Synthesis and characterization of new low-molecular-weight lysine-conjugated Gd-DTPA contrast agents.

26. In vitro biomedical applications of functionalized iron oxide nanoparticles, including those not related to magnetic properties.

27. Synthesis and physicochemical characterization of new squalenoyl amphiphilic gadolinium complexes as nanoparticle contrast agents.

28. Superparamagnetic nanosystems based on iron oxide nanoparticles for biomedical imaging.

29. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease.

30. Towards MRI contrast agents responsive to Ca(II) and Mg(II) ions: metal-induced oligomerization of dota-bisphosphonate conjugates.

31. Iron oxide particles covered with hexapeptides targeted at phosphatidylserine as MR biomarkers of tumor cell death.

32. Liposomes with conjugates of a calix[4]arene and a Gd-DOTA derivative on the outside surface; an efficient potential contrast agent for MRI.

33. Synthesis and physicochemical characterization of Gd-C4-thyroxin-DTPA, a potential MRI contrast agent. Evaluation of its affinity for human serum albumin by proton relaxometry, NMR diffusometry, and electrospray mass spectrometry.

34. Magnetic iron oxide nanoparticles for biomedical applications.

35. Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques.

36. Lanthanide complexes on Ag nanoparticles: designing contrast agents for magnetic resonance imaging.

37. Study of non-covalent interactions between MRI contrast agents and human serum albumin by NMR diffusometry.

38. Iron oxide based MR contrast agents: from chemistry to cell labeling.

39. Magnetic labeling of non-phagocytic adherent cells with iron oxide nanoparticles: a comprehensive study.

40. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications.

41. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA.

42. Contrast agents: magnetic resonance.

43. Comparative analysis of the 1H NMR relaxation enhancement produced by iron oxide and core-shell iron-iron oxide nanoparticles.

44. In vitro characterization of the Gd complex of [2,6-pyridinediylbis(methylene nitrilo)] tetraacetic acid (PMN-tetraacetic acid) and of its Eu analogue, suitable bimodal contrast agents for MRI and optical imaging.

45. The presence of halide salts influences the non-covalent interaction of MRI contrast agents and human serum albumin.

46. Comprehensive investigation of the non-covalent binding of MRI contrast agents with human serum albumin.

47. From phage display to magnetophage, a new tool for magnetic resonance molecular imaging.

48. A glycosylated complex of gadolinium, a new potential contrast agent for magnetic resonance angiography?

49. Relaxometric and magnetic characterization of ultrasmall iron oxide nanoparticles with high magnetization. Evaluation as potential T1 magnetic resonance imaging contrast agents for molecular imaging.

50. Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity.

Catalog

Books, media, physical & digital resources